Vallon Pharma Q3 net loss $1.0M; cash $5.2M; strategic review ongoing

GRI Bio, Inc.

2022-Q3 EPS reported -$0.59

Net loss of $1.0M for Q3 2022; R&D expenses reversed to $(18,000) vs $0.2M in Q3 2021.
G&A expenses $1.4M, up from $1.0M, driven by $0.6M in strategic evaluation costs.
Cash, cash equivalents and marketable securities of $5.2M as of Sept 30, 2022.
Strategic alternatives review with Ladenburg Thalmann remains ongoing; no transaction guaranteed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GRI Bio, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Vallon Pharmaceuticals, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-22-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.